tiprankstipranks
Trending News
More News >

Solasia Pharma Revises Fiscal 2024 Earnings Forecast with New China Sales Agreement

Story Highlights
  • Solasia Pharma revises 2024 earnings forecast due to new China sales agreement.
  • Revenue expected to increase by 140 million yen, with a forecasted operating loss of 1,050 million yen.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Solasia Pharma Revises Fiscal 2024 Earnings Forecast with New China Sales Agreement

Don’t Miss TipRanks’ Half-Year Sale

Solasia Pharma KK ( (JP:4597) ) has issued an announcement.

Solasia Pharma K.K. has revised its earnings forecast for the fiscal year ending December 31, 2024, due to a new agreement with Changchun GeneScience Pharmaceutical Co., Ltd. for the exclusive sales rights of episil® in China. The company expects an increase in revenue by 140 million yen from previous forecasts, largely attributed to a lump-sum contract payment and sales royalties from GenSci. However, despite the increased revenue, the company forecasts an operating loss of 1,050 million yen, which is an improvement from the previous estimate due to adjustments in R&D and SG&A expenses.

More about Solasia Pharma KK

Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative oncology medicines. The company has a significant market presence in Asia, particularly in China, where it collaborates with local pharmaceutical partners to enhance its product distribution.

YTD Price Performance: 3.68%

Average Trading Volume: 196

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: €48.39M

See more insights into 4597 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1